The South African regulator approved the manufacture and marketing of the generic version of semaglutide injection in South Africa to supplement dietary protocols and exercise to treat adults with inadequately controlled type 2 diabetes, says Sun Pharmaceutical Industries said in a regulatory filing
Read more: India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales
The manufacturer says that it plans to launch the product in the market in the coming day—available in pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing.
“South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals,” says Sun Pharma Chief Operating Officer Aalok Shanghvi.
Read more: Dr Reddy’s pauses weight loss drug on quality fears
Type 2 diabetes is a growing concern in South Africa which is being driven by rapid urbanisation and changing lifestyles, says the company and further added that the disease’s rising prevalence placed a significant pressure on patients and healthcare service. The company emphasised that improving access to effective therapies is therefore an important component of addressing the nation’s health challenge